Group 1 (+/+) | Group 2 (+/−) | Group 3 (−/ +) | Group 4 (−/−) | |
---|---|---|---|---|
No. of patients | 8/32 (25%) | 10/32 (31.25%) | 6/32 (18.75%) | 8/32 (25%) |
Sex | ||||
Female | 4 (50%) | 9 (90%) | 4 (66.7%) | 4 (50%) |
Male | 4 (50%) | 1 (10%) | 2 (33.3%) | 4 (50%) |
Mean age | 73.6 ± 9.3 (range 53–85) | 71.2 ± 5.7 (range 56–77) | 74.5 ± 3.0 (range 71–79) | 77.0 ± 5.3 (range 67–86) |
Symptoms duration (months) | 18.3 ± 2.7 (range 12–24) | 21.6 ± 7.3 (range 12–30) | 23.2 ± 6.8 (range 12–30) | 37.8 ± 5.4 (range 30–48) |
mFI-11 | 4.7 ± 1.1 (range 1–6) | 5.2 ± 1.7 (range 0–7) | 5.3 ± 2.9 (range 2–8) | 7.8 ± 2.1 (range 4–10) |
Neuroradiological parameters | ||||
EI | 0.39 ± 0.03 (range 0.33–0.45) | 0.38 ± 0.05 (range 0.32–0.47) | 0.36 ± 0.04 (range 0.30–0.43) | 0.37 ± 0.04 (range 0.31–0.41) |
CA | 94.3° ± 24.1° (range 63°–130°) | 95.0° ± 19.4° (range 65°–129°) | 100.7° ± 19.4° (range 79°–130°) | 96.9° ± 12.6° (range 79°–103°) |
DESH | 5 (62.5%) | 8 (80%) | 4 (66.7%) | 2 (25%) |
Infusion test | ||||
Rout | 13.20 ± 1.00 (range 12.00–15.00) | 13.39 ± 1.29 (range 12.00–16.00) | 9.56 ± 1.79 (range 6.00–11.33) | 8.98 ± 1.43 (range 6.67–11.33) |
TUG | ||||
Pre-test value | 22.56 ± 15.39 (range 13.0–61.0) | 18.15 ± 15.75 (range 10.5–65.0) | 17.33 ± 12.90 (range 10.0–46.0) | 15.13 ± 3.77 (range 10.5–22.0) |
Post-test value | 18.81 ± 13.73 (range 9.5–54.0) | 17.90 ± 15.87 (range 10.0–65.0) | 12.67 ± 7.76 (range 9.0–30.0) | 15.94 ± 4.68 (range 10.5–23.0) |
Improvement (%) | 17.47 ± 5.89 (range 10.71–26.20) | 1.73 ± 6.97 (range −11.76–9.09) | 22.21 ± 8.87 (range 10.00–34.78) | −4.73 ± 11.35 (range −25.71–8.33) |
MN | ||||
Pre-test value | 12.24 ± 2.92 (range 7.94–17.01) | 9.96 ± 1.65 (range 7.37–13.33) | 13.04 ± 2.27 (range 8.66–16.09) | 11.92 ± 2.10 (range 7.45–13.96) |
Post-test value | 15.38 ± 1.87 (range 12.18–18.95) | 12.97 ± 2.96 (range 8.06–17.38) | 14.95 ± 2.40 (range 10.38–17.54) | 10.73 ± 1.70 (range 8.06–13.56) |
Improvement (%) | 30.73 ± 26.46 (range 7.81–91.06) | 30.16 ± 21.14 (range 2.94–66.63) | 15.28 ± 9.21 (range 4.40–31.99) | −0.20 ± 31.25 (range −25.65–59.19) |
DMN | ||||
Pre-test value | 12.98 ± 3.97 (range 6.77–18.33) | 14.24 ± 4.42 (range 9.78–26.31) | 12.57 ± 2.29 (range 10.04–16.06) | 14.30 ± 3.09 (range 10.40–18.56) |
Post-test value | 17.05 ± 2.67 (range 12.56–21.59) | 18.31 ± 4.74 (range 14.02–30.81) | 16.60 ± 1.59 (range 14.47–19.00) | 13.44 ± 3.67 (range 7.54–18.59) |
Improvement (%) | 41.06 ± 39.92 (range 7.26–139.44) | 32.56 ± 26.71 (range 2.57–86.07) | 34.12 ± 11.34 (range 18.31–44.47) | −3.63 ± 30.71 (range -31.02–49.29) |
Surgery | ||||
VPS implantation | 8/8 (100%) | 10/10 (100%) | 6/6 (100%) | 8/8 (100%) |
Clinical Improvement | 8/8 (100%) | 10/10 (100%) | 6/6 (100%) | 2/8 (25%) |